U.S. Markets closed
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • Dow 30

    33,978.08
    +28.68 (+0.08%)
     
  • Nasdaq

    11,621.71
    +109.31 (+0.95%)
     
  • Russell 2000

    1,911.46
    +8.40 (+0.44%)
     
  • Crude Oil

    79.38
    -1.63 (-2.01%)
     
  • Gold

    1,943.90
    -2.80 (-0.14%)
     
  • Silver

    23.73
    -0.30 (-1.25%)
     
  • EUR/USD

    1.0871
    -0.0021 (-0.1957%)
     
  • 10-Yr Bond

    3.5180
    +0.0250 (+0.72%)
     
  • Vix

    18.51
    -0.22 (-1.17%)
     
  • GBP/USD

    1.2399
    -0.0008 (-0.0608%)
     
  • USD/JPY

    129.6640
    -0.4890 (-0.3757%)
     
  • BTC-USD

    23,812.35
    +798.65 (+3.47%)
     
  • CMC Crypto 200

    526.66
    +9.65 (+1.87%)
     
  • FTSE 100

    7,765.15
    +4.04 (+0.05%)
     
  • Nikkei 225

    27,382.56
    +19.76 (+0.07%)
     

Economic Challenges Hit Edwards Lifesciences Q3 Earnings, Guidance Lags Wall Street Estimates

  • Edwards Lifesciences Corp (NYSE: EW) reported Q3 adjusted EPS of $0.61, up 13% Y/Y, missing the Wall Street consensus of $0.62.

  • The company saw persistent U.S. hospital staffing shortages and COVID headwinds in Japan affect its TAVR sales.

  • Edwards' TAVR sales only grew 1% Y/Y in Q3, reaching $862 million. In the U.S., Edwards' TAVR procedures increased in the mid-single digits versus the prior year.

  • Q3 sales reached $1.32 billion, up 1% (+7% on constant currency), slightly below the consensus of $1.33.

  • Edwards Lifesciences regulatory wins during Q3 included FDA approval and the CE Mark of its Pascal Precision system for patients with degenerative mitral regurgitation (DMR).

  • Guidance: Edwards Lifesciences suspect that U.S. hospital staffing challenges and a strong U.S. dollar will persist.

  • The company revised FY22 sales guidance at the low end of the company's previous range of $5.35-$5.55 billion, compared to the consensus of $5.47 billion.

  • It projects an FY22 adjusted EPS of $2.40-$2.50, down from the previous range of $2.50-$2.65 and the consensus of $2.51.

  • For Q4, Edwards expects reported sales and adjusted EPS to be similar to the third quarter.

  • Price Action: EW shares are down 15.9% at $72.57 on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.